Designing Longevity
Skip to main content
Moderate EvidencePeptide

Pramlintide

Amylin analogue

Last updated: November 2026
Share:

Pramlintide is an amylin analogue. Its labeled role was as an add-on to mealtime insulin for selected people with type 1 or type 2 diabetes who had not met their blood sugar goals despite optimized insulin treatment. MedlinePlus reports the injection was discontinued in the United States.

Evidence Level: Moderate Evidence

Some human data, strong animal studies, plausible mechanism

Regulatory Status: SymlinPen has FDA labeling for a defined diabetes use. MedlinePlus reports that the injection was discontinued in the United States.

How It Works

The label describes slowing stomach emptying and reducing the rise in blood sugar that can follow a meal.

Potential Benefits

  • The approved labeling describes blood sugar outcomes in selected people using mealtime insulin.

Risks & Considerations

  • The boxed warning describes severe low blood sugar when used with insulin. The label requires close clinical supervision.

Sources and regulatory records

Disclaimer: This information is for educational purposes only and is not medical advice. Many peptides discussed are not FDA-approved for human use. Always consult with a qualified healthcare provider before starting any treatment. Evidence levels and regulatory status can change, this content was last updated November 2026.

Found this helpful? Share it or save it for later.

Share:

See a problem or outdated information? Tell us.